Prof. Satu Mustjoki, University of Helsinki, Finland

host: Riitta Lahesmaa (riitta.lahesmaa@utu.fi)

Dr. Satu Mustjoki, MD, PhD is a professor of Translational Hematology at the University of Helsinki, Finland and a specialist in Clinical Chemistry (laboratory hematology). She has led several translational immunological biomarker studies in conjunction with the international clinical trials in leukemia. Her current research focuses on tumor immunology and on the molecular mechanisms of T-cell malignancies and associated autoimmune disorders and is supported by ERC among several other national and international awards (www.helsinki.fi/hematology). She leads the Translational Immunology Research Program at the Faculty of Medicine, University of Helsinki, Finland (www.helsinki.fi/trimm). She has > 140 publications including those published in New England Journal of Medicine, Nature Genetics, Nature Communications, Blood, and Cancer Cell.

Selected publications

Dufva O*, Polonen P*, Bruck O, Keranen MAI, Klievink J, Mehtonen J, Huuhtanen J, Kumar A, Malani D, Siitonen S, Kankainen M, Ghimire B, Lahtela J, Mattila P, Vaha-Koskela M, Wennerberg K, Granberg K, Leivonen SK, Meriranta L, Heckman C, Leppa S, Nykter M, Lohi O, Heinaniemi M*, Mustjoki S*. 2020.  Immunogenomic Landscape of Hematological Malignancies. Cancer Cell.
https://dx.doi.org/10.1016/j.ccell.2020.06.002 *shared

Kim D, Park G, Huuhtanen J, Lundgren S, Khajuria RK, Hurtado AM, Munoz-Calleja C, Cardenoso L, Gomez-Garcia de Soria V, Chen-Liang TH, Eldfors S, Ellonen P, Hannula S, Kankainen M, Bruck O, Kreutzman A, Salmenniemi U, Lonnberg T, Jerez A, Itala-Remes M, Myllymaki M, Keranen MAI, Mustjoki S. 2020. Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease. Nat Commun. 11: 2246

Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J, Polonen P, Hohtari H, Saeed K, Hannunen T, Ellonen P, Steinberger P, Kankainen M, Aittokallio T, Keranen MAI, Korhonen M, Mustjoki S. 2020. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood. 135: 597-609

Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmaki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP, Jr., Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S. 2018. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 9: 1567

Savola P, Kelkka T, Rajala HL, Kuuliala A, Kuuliala K, Eldfors S, Ellonen P, Lagstrom S, Lepisto M, Hannunen T, Andersson EI, Khajuria RK, Jaatinen T, Koivuniemi R, Repo H, Saarela J, Porkka K, Leirisalo-Repo M, Mustjoki S. 2017. Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. Nat Commun. 8: 15869

Genral info regarding the Frontiers of Science eTALKs

• Registration is obligatory and links to register to all Frontiers of Science Autumn 2020 seminars are available in BioCity Turku webpage (https://biocityturku.fi/biocityevents/frontiers-of-science-seminars/programme-autumn-2020/) and in our news feed.
• Registration closes two days before the event and link to join zoom will be sent to the participants one day in advance.
• Microphones and cameras need to be turned off during the presentation, but the audience is welcome to ask questions after the talk, preferably with video turned on to make the discussion as interactive as possible.
• If you are a student and need a certificate for your attendance, please fill in your student number when registering to the events. After the seminar season is over, please contact BioCity Turku coordinator biocityturku@bioscience.fi.

If you have any questions regarding our Frontiers of Science eTALK seminar series, please don’t hesitate to contact BioCity Turku coordinator biocityturku@bioscience.fi